Drug-Induced Acute Myocardial Infarction: Identifying ‘Prime Suspects’ from Electronic Healthcare Records-Based Surveillance System

Abstract

BackgroundDrug-related adverse events remain an important cause of morbidity and mortality and impose huge burden on healthcare costs. Routinely collected electronic healthcare data give a good snapshot of how drugs are being used in ‘real-world’ settings.ObjectiveTo describe a strategy that identifies potentially drug-induced acute myocardial infarction (AMI) from a large international healthcare data network.MethodsPost-marketing safety surveillance was conducted in seven population-based healthcare databases in three countries (Denmark, Italy, and the Netherlands) using anonymised demographic, clinical, and prescription/dispensing data representing 21,171,291 individuals with 154,474,063 person-years of follow-up in the period 1996–2010. Primary care physicians’ medical records and administrative claims containing reimbursements for filled prescriptions, laboratory tests, and hospitalisations were evaluated using a three-tier triage system of detection, filtering, and substantiation that generated a list of drugs potentially associated with AMI. Outcome of interest was statistically significant increased risk of AMI during drug exposure that has not been previously described in current literature and is biologically plausible.ResultsOverall, 163 drugs were identified to be associated with increased risk of AMI during preliminary screening. Of these, 124 drugs were eliminated after adjustment for possible bias and confounding. With subsequent application of criteria for novelty and biological plausibility, association with AMI remained for nine drugs (‘prime suspects’): azithromycin; erythromycin; roxithromycin; metoclopramide; cisapride; domperidone; betamethasone; fluconazole; and megestrol acetate.LimitationsAlthough global health status, co-morbidities, and time-invariant factors were adjusted for, residual confounding cannot be ruled out.ConclusionA strategy to identify potentially drug-induced AMI from electronic healthcare data has been proposed that takes into account not only statistical association, but also public health relevance, novelty, and biological plausibility. Although this strategy needs to be further evaluated using other healthcare data sources, the list of ‘prime suspects’ makes a good starting point for further clinical, laboratory, and epidemiologic investigation.

Prevalence and Incidence of Epilepsy in Italy Based on a Nationwide Database

“…The validity of the HSD data for conducting epidemiological studies has been confirmed elsewhere [8,9,10,11,12,13,14,15]. …”

Early impact of the ICD‐10‐CM transition on selected health outcomes in 13 electronic health care databases in the United States

“…We defined each health outcome in the ICD‐10‐CM era in 4 ways. Definition 1 involved abstracting or deriving algorithms based on previous, published work ( Information ) . Definition 2 involved simple forward mapping (SFM) from the ICD‐9‐CM era definition to ICD‐10‐CM codes by referencing the 2017 General Equivalence Mappings (GEMs; see below for description) .…”

Managing Cardiovascular Risk of Macrolides: Systematic Review and Meta-Analysis

“…We further screened and evaluated 296 records and subsequently excluded 246 records as they were not observational studies, RCTs, or using other macrolides as comparators. One study was excluded as it was a pharmacovigilance signal generation study without any hypothesis driven process [26]. Another study which was written in languages other than English or Chinese was also excluded [27].…”

“…In the stratified analysis, we could only demonstrate that erythromycin increased the short-term risk of cardiac death, clarithromycin increased the short-term risk of myocardial infarction, while azithromycin increased the short-term risk of arrhythmia in observational studies. However, one pharmacovigilance study using healthcare data from three European countries found an increased risk of myocardial infarction associated with clarithromycin, azithromycin, roxithromycin and erythromycin individually during the current exposure using several observational study designs [26]. Due to the limited number of studies for macrolides other than clarithromycin, we could not rule out the possibility that macrolides have a class effect upon acute myocardial infarction.…”